Analysis of Concentrations of Monomethyl Fumarate in Patients with Multiple Sclerosis: Result from Routine Health Care

Title:Analysis of Concentrations of Monomethyl Fumarate in Patients with Multiple Sclerosis: Result from Routine Health Care

Volume: 23 Issue: 12

Author(s): Zuzana Krska Kusnirikova, Ivana Kacirova, Veronika Pesakova, Pavel Hradilek, Hana Brozmanova and Milan Grundmann*

Affiliation:

• Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic
• Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17, Listopadu 1790/5, 70852 Ostrava, Czech Republic

Keywords: Analysis, concentration, dimethyl fumarate, monomethyl fumarate, multiple sclerosis, health care.

Abstract:

Background: Dimethyl fumarate is used to treat patients with relapsing-remitting multiple sclerosis. After ingestion, it is rapidly hydrolyzed to the active primary metabolite monomethyl fumarate.

Objective: The main objective of our study was to analyze serum concentrations of monomethyl fumarate during routine health care in patients with multiple sclerosis treated with a fixed dose of dimethyl fumarate.

Methods: In the pilot cross-sectional study, data from 42 patients treated with dimethyl fumarate at a dose of 240 mg twice daily were collected. Concentrations of the active metabolite monomethyl fumarate were determined at 1-8 h (median, 3 h) or 10-14 h (median, 13 h) after taking the dose. The relationship between monomethyl fumarate concentrations and absolute lymphocyte count was evaluated.

Results: Concentrations of monomethyl fumarate ranged from 2.5-3177.9 μg/L, with most concentrations being undetectable approximately 10 hours after administration. In the 1-8 h (median, 3 h) post-dose subgroup, the concentration/dose ratio ranged widely from 0.04-6.62.

The median concentration of monomethyl fumarate in the group with the absolute lymphocyte count <0.8 x 10^9/L was more than four times higher than in the group with the absolute lymphocyte count ≥0.8 x 10^9/L (median 440.1 μg/L versus 98.4 μg/L).

Conclusion: The wide interindividual variability in monomethyl fumarate pharmacokinetics could contribute to the differential response to dimethyl fumarate in multiple sclerosis patients. A nonsignificant but noticeable trend was observed in the relationship of higher serum monomethyl fumarate concentrations to absolute lymphocyte counts.

Cite this article as:

Kusnirikova Krska Zuzana, Kacirova Ivana, Pesakova Veronika, Hradilek Pavel, Brozmanova Hana and Grundmann Milan*, Analysis of Concentrations of Monomethyl Fumarate in Patients with Multiple Sclerosis: Result from Routine Health Care, CNS & Neurological Disorders - Drug Targets 2024; 23 (12) . https://dx.doi.org/10.2174/0118715273302279240529104919